Please login to the form below

Not currently logged in
Email:
Password:

Fishawack acquires Dudnyk

Agency to boost abilities in rare diseases and oncology

Dudnyk

Fishawack has given its rare diseases and oncology capabilities a boost after it announced it will acquire US-based healthcare communications agency Dudnyk (pictured above).

Dudnyk specialises in insight-driven brand solutions for speciality physicians and their patients, and has worked on briefs for Shire, Alnylam and Jazz Pharmaceuticals.

“Dudnyk brings to Fishawack a particular expertise in rare diseases, oncology, and launching breakthrough molecular medicines,” explains Christopher Tobias, President of Dudnyk. “Our seasoned team will complement Fishawack’s already expansive offering, especially in the area of commercial strategy and creative expertise.”

The move allows Fishawack to build on its goal of increasing the range of healthcare communications services that it can offer to its clients. It now has healthcare creative agencies that span East to West Coast USA and Europe.

“Fishawack has wanted to add an East-coast healthcare marketing agency of scale and is pleased to have found that partnership with Dudnyk,” explains Oliver Dennis, CEO of Fishawack Group of Companies. “The leadership at Dudnyk clearly cares about their people, their clients, and the rare disease and oncology patients they serve. The organisation’s values are very much aligned with ours.”

The company is currently undergoing a rebranding, which it says will better reflect its core beliefs.

“Fishawack is unlike traditional networks that make introductions as client needs arise; instead, we form high-performing inter-company business relationships early on,” adds Dennis.

“This is important to our clients who depend on continuity of relationships and teams they can depend on.”

This is the second acquisition the group has made within three months after it bought marketing consultancy Blue Latitude Health back in December.

However, Gail Flockhart, Group President confirms that “it’s not just about acquiring”.

“It’s about making the synergies real, which means connecting talent across the organisation. The best part of every acquisition is discovering what we can learn from each other.”

Article by
Gemma Jones

22nd March 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics